

Message

From: Lisa Lefferts [llefferts@cspinet.org]
Sent: 3/28/2016 3:23:29 PM
To: Cogliano, Vincent [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=51f2736376ac4d32bad2fe7cfef2886b-Cogliano, Vincent]
Subject: FW: question about use of RI data

Importance: High

Dear Dr. Cogliano

I am hoping to reach you to clarify a scientific matter regarding Ramazzini Institute data, and its use by EPA for IRIS assessments, as per my email from 3/16 (below) and recent phone call.

The EPA website update on RI data in IRIS assessments is a bit cryptic as to whether it applies to RI rat studies only, or to all RI studies. My understanding is that it was in response to earlier concerns regarding diagnoses of lymphomas/leukemias, which were all made in rats. This table from the Gift et al publication by EPA scientists states **"Consistency in lymphoma/leukemia diagnoses was reported in the RI mouse study review** (Cesta 2008), but only partial consistency was found in RI **rat** studies, especially the RI methanol study (EPL 2011b). Hailey (2004) reported diagnostic consistency **in rats** in a limited review of lymphoma subtypes (e.g., lymphocytic, histiocytic, monocytic, and/or myeloid origin)."

Is the issue of diagnostic uncertainty only a concern for rat lymphomas/leukemias in RI studies?

Would EPA use data from RI studies in mice?

You can reach me at 4 Personal Phone / Ex. 6 Thank you very much.

Lisa Y. Lefferts, MSPH
Senior Scientist
Center for Science in the Public Interest
1220 L Street, NW, Suite 300
Washington, DC 20005
phone: 202-777-8317
LLefferts@cspinet.org
www.cspinet.org

From: Lisa Lefferts
Sent: Wednesday, March 16, 2016 4:56 PM
To: 'cogliano.vincent@epa.gov' <cogliano.vincent@epa.gov>
Subject: question about use of RI data
Importance: High

Dear Dr. Cogliano

Is it correct that EPA's policy is to not rely on lymphoma and leukemia data from Ramazzini Institute (RI) *rat* studies in IRIS assessments, but that it would use lymphoma and leukemia data from Ramazzini Institute (RI) *mouse* studies? And that it would use data from other target organs in RI rat studies (i.e, excluding lymphomas/leukemias)? Just wanted to doublecheck.

My understanding from the 2013 paper by Gift et al is that EPA policy regarding not relying on lymphoma and leukemia data from Ramazzini Institute (RI) studies in IRIS assessments was in response to concerns regarding diagnoses of

lymphomas and leukemias in *rats*, and that the diagnosis of these cancers, as well as other cancers in RI studies in *mice*, is not at issue.

Hoping you can confirm.

Thanks very much.

Lisa Y. Lefferts, MSPH
Senior Scientist
Center for Science in the Public Interest
1220 L Street, NW, Suite 300
Washington, DC 20005
phone: 202-777-8317
LLefferts@cspinet.org
www.cspinet.org